|
Research Interests:
Dr. Dabbs has primary interest in breast pathology and immunohistochemistry. Dr. Dabbs is Editor and co-author of the soon-to-be-released First Edition of
Breast Pathology (Spring, 2012, Elsevier, NY), a collaborative work of international contributors, the first book of its kind in the United States. Dr. Dabbs is also Editor and co-author of Diagnostic Immunohistochemistry, in its Third Edition (2010, Elsevier, NY). His expertise extends to gynecologic and surgical pathology, and he is currently the Chief Diagnostic Consultant for US Labs, based in Irvine, CA. Dr. Dabbs serves as Division Chief for Women's Heath, and is Chief of Pathology at Magee-Women's Hospital, and Director of the Magee Breast/Gynecologic Pathology Fellowship at Magee.
Selected Publications:
View Dr. Dabbs' publications on PubMed.
Rollins-Raval M, Chivukula M, Tseng GC, Jukic D, Dabbs DJ. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature.Arch Pathol Lab Med. 2011 Aug;135(8):975-83.
Dabbs DJ, Bhargava R. Fixation time does not affect the expression of estrogen receptor. Am J Clin Pathol. 2011 Jan;135(1):171-2. author reply.
Bhargava R, Beriwal S, McManus K, Dabbs DJ. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl Immunohistochem Mol Morphol. 2011 May;19(3):218-25.
Yu J, Dabbs DJ, Shuai Y, Niemeier LA, Bhargava R. Classical-Type Invasive Lobular Carcinoma With HER2 Overexpression: Clinical, Histologic, and Hormone Receptor Characteristics. Am J Clin Pathol. 2011 Jul;136(1):88-97.
Bhargava R, Esposito NN, Dabbs DJ. Intracystic papillary carcinomas of the breast are more similar to in situ carcinomas than to invasive carcinoma.Am J Surg Pathol. 2011 May;35(5):778-9; author reply 779-81.
Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP, Ahrendt GM. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol. 2010 Nov 19.
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS.Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2010 Nov 12.
Breast cancer prognostic classification in the molecular era: the role of histological grade. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse GM, Badve S, Ellis IO. Breast Cancer Res. 2010;12(4):207.
Jones MW, Harri R, Dabbs DJ, Carter GJ. Immunohistochemical profile of steroid cell tumor of the ovary: a study of 14 cases and a review of the literature. Int J Gynecol Pathol 2010 Jul:29(4):315-20.
Yu J, Bhargava R, Dabbs DJ. Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: A case report and further case studies. Diagn Pathol 2010 Jun 15;5:36.
|
